PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33200796-0	2021	Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.	osimertinib	111-122	BCL2 apoptosis regulator	Homo sapiens	14-19	
33376097-15	2021	Further study of BCL-2/BCL-xL inhibition to enhance osimertinib activity is warranted.	osimertinib	52-63	BCL2 apoptosis regulator	Homo sapiens	17-22	
33200796-5	2021	Furthermore, the suppression of Bcl-2 and Bcl-xL through small interfering RNA-mediated gene knockdown or using a small molecule specific inhibitor ABT-263 re-sensitized HCC827/OR cells to osimertinib treatment.	osimertinib	189-200	BCL2 apoptosis regulator	Homo sapiens	32-37	
32577785-0	2020	Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells.	osimertinib	94-101	BCL2 apoptosis regulator	Homo sapiens	23-28	
32577785-3	2020	In the present study, significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells (H1975AR) compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291.	osimertinib	69-76	BCL2 apoptosis regulator	Homo sapiens	50-55	
32577785-3	2020	In the present study, significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells (H1975AR) compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291.	osimertinib	210-217	BCL2 apoptosis regulator	Homo sapiens	50-55	
32577785-4	2020	More importantly, our study showed that synergism between AZD9291 and Bcl-2 inhibitor ABT263 (0.25 muM) or ABT199 (1 muM) could effectively overcome the acquired resistance of AZD9291 in H1975AR in vitro.	osimertinib	176-183	BCL2 apoptosis regulator	Homo sapiens	70-75